Abstract
Effective prophylaxis against specific infections has allowed increasingly potent conditioning regimens to be given, thereby prolonging survival in HSCT recipients. The Centers for Disease Control and Prevention, in collaboration with numerous professional societies, has recently published guidelines to codify and advance this approach. Controversy remains in several areas but, curiously, the most intense debate concerns prevention of bacterial infections, the most extensively studied of all of the approaches. Central to this debate are the competing priorities of a potentially ill patient on the one hand vs the long-term consequences of unchecked antibiotic use. The emergence in the 1990s of vancomycin-resistant Enterococcus demonstrated all too vividly how devastating such an end result could be. This article will review the arguments for and against the routine use of antibacterial prophylaxis in HSCT recipients.
Bone Marrow Transplantation (2002) 29, 367–371. doi:10.1038/sj.bmt.1703366
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Centers for Disease Control and Surveillance. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of the CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow transplantation MMWR Morb Mortal Wkly Rev 2000 49: 1 125
Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis Clin Infect Dis 1996 23: 795 805
Engels EA, Lau J, Barza M . Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis J Clin Oncol 1998 16: 1179 1187
Nagatomo A, Watanabe K, Kunikane H et al. A randomized controlled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethoxazole/trimethoprim alone for the prophylaxis of bacteria infection during chemotherapy for lung cancer Lung Cancer 1998 19: 121 125
Murphy M, Brown AE, Sepkowitz KA et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer Clin Infect Dis 1997 25: 346 347
De Pauw BE, Donnelly JP . Infections in the immunocompromised host: general principles. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and Practice of Infectious Disease,5th edn Churchill-Livingstone: Philadelphia, PA 2000 3079 3090
Baum HV, Franz U, Geiss HK . Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic–oncologic patients Infection 2000 28: 278 281
Yeh SP, Hsueh EJ, Yu MS et al. Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal Bone Marrow Transplant 1999 24: 1207 1211
Beelen DW, Elmaagacli A, Muller KD et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial Blood 1999 93: 3267 3275
Carlens S, Ringden O, Aschan J et al. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination Clin Transplant 1998 12: 84 92
Cometta A, Calandra T, Bille J, Glauser MP . Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia New Engl J Med 1994 330: 1240 1241
Low DE, Keller N, Barth A, Jones RN . Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997–1999 Clin Infect Dis 2001 32: (Suppl. 2) S133 S145
Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 2001 358: 207 208
Gonzales RD, Schreckenberger PC, Graham MB et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid Lancet 2001 357: 1179
Attal M, Schlaifer D, Rubie H et al. Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial J Clin Oncol 1991 9: 865 870
Elting LS, Bodey GP, Keefe BH . Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors Clin Infect Dis 1992 14: 1201 1207
Bochud PY, Eggiman P, Calandra T et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors Clin Infect Dis 1994 18: 25 31
Marron A, Carratala J, Gonzalez-Barca E et al. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer Clin Infect Dis 2000 31: 1126 1130
Bochud PY, Calandra T, Francioli P . Bacteremia due to viridans streptococci in neutropenic patients: a review Am J Med 1994 97: 256 264
Diekema DJ, Beach ML, Pfaller MA, Jones RN . Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America Clin Microbiol Infect 2001 7: 152 157
Alfieri N, Ramotar K, Armstrong P et al. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing Infect Control Hosp Epidemiol 1999 20: 553 556
Bergogne-Berezin E . The increasing role of Acinetobacter species as nosocomial pathogens Curr Infect Dis Rep 2001 5: 440 444
Donskey CJ, Chowdhry TK, Hecker MT et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients New Engl J Med 2000 343: 1925 1932
Lee CE, Zembower TR, Fotis MA et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance Arch Intern Med 2000 160: 2819 2822
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sepkowitz, K. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow Transplant 29, 367–371 (2002). https://doi.org/10.1038/sj.bmt.1703366
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703366
Keywords
This article is cited by
-
Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms—Where Are We Today?
Current Hematologic Malignancy Reports (2018)
-
The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience
European Journal of Clinical Microbiology & Infectious Diseases (2012)
-
Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin–tazobactam
Bone Marrow Transplantation (2005)